4 copies of the ABL housekeeping gene. They reported that on achievement of complete remission (CR), the mean copy number was significantly higher in patients who later relapsed than in those who went on to attain continuous CR (CCR) (151 vs 9, Po0.0001 by Mann-Whitney test). Moreover, in patients who maintained CCR, the copy number subsequently dropped below the detection threshold and remained undetectable. By contrast, in the 7/16 patients who relapsed, the copy number never dropped to the minimum detection level. Thus, a cutoff value discriminating these two groups of patients could be inferred at one copy of CBFb/MYH11 per 10 4 copies of ABL. The authors invited confirmation of the predictive value of real-time PCR determination of MRD in AML patients with inv(16). We 2 and others 3, 4 have reported the use of very similar realtime RT-PCR methods for determining MRD (in our case, at least, in accordance with the same European Concerted Action guidelines) in AML patients carrying the CBFb/MYH11 5, 6 fusion transcript in association with inv(16). In 19 consecutive patients, we retrospectively analyzed the CBFb-MYH11/ABL ratios of peri/post-treatment samples from nonrelapsing (group A) and relapsing (group B) patients, and of samples obtained at the time of diagnosis or relapse (group C). We have now recalculated our data, expressing them, like Guerrasio et al, 1 as CBFb/MYH11-copy numbers per 10 4 copies of ABL. The differences among the three groups were all highly significant (Kruskal-Wallis test, Po0.0001). At diagnosis or relapse (group C), the CBFb-MYH11/ABL ratio ranged from 1900 to 6000. Ratios (n ¼ 101) obtained during or after treatment from patients who did not relapse (group A) were always 25 or less (minimum, 0). By contrast, ratios obtained during or after treatment from patients who did relapse (group B) were always 12 or more (maximum, 710). Among the six assays that fell within the intermediate gray zone (ie 12-25), three referred to two patients who went on to relapse and three to three patients who maintained CCR. We concluded that transcript ratios greater than 25 indicate a high risk of relapse, whereas values below 12 suggest a curable state.
Thus, the study by Guerrasio et al 1 provides confirmation of our previous observation that CCR status is achieved below a threshold level of 12 CBFb/MYH11 copy numbers per 10 . As regards prediction of relapse, there was a small difference in the threshold levels below which CCR appeared likely in our study and that by Guerrasio et al 1 (12 vs 1 CBFb/ MYH11copies per 10 4 copies of ABL). This slight discrepancy could be because of the different sampling times with respect to the therapy programs. Therefore, it could be interesting to monitor patients on completion of their therapeutic program at identical time points and sampling modality (always bone marrow). Furthermore, different chemotherapy protocols could account for small differences in MRD: based on the favorable updated overall and relapse-free survival results of our series (manuscript submitted), we recommend application of our ICE/FLAN/FLAN/ ABMT protocol 7 for AML inv(16)-positive patients. Finally, both studies identified a threshold levels above which relapse tends to occur: in our case, ratios greater than 25 CBFb/MYH11 per 10 4 copies of ABL transcript indicate a high risk for relapse.
Regarding the other reported studies, Krauter et al 4 also used a similar real-time RT-PCR assay for the quantification of CBFb/ MYH11 transcripts, but failed to find any association with clinical response or relapse rate. More significantly, Marcucci et al 3 and Krauter et al 4 analyzed bone marrow samples from 16 patients with inv(16) AML enrolled on a German multicenter trial (AML HD93) for levels of CBFb/MYH11 fusion transcripts by real-time RT-PCR at diagnosis (n ¼ 14), during remission (n ¼ 10), and at relapse (n ¼ 6). The CBFb/MYH11 transcript copy number in each sample was normalized to copies of a different internal control housekeeping transcript (ie 18S instead of ABL). No difference in levels of CBFb/MYH11 fusion transcripts measured during intensification therapy was found between patients destined to relapse and those who maintained CCR. However, following completion of the entire chemotherapy program, patients who showed a CBFb/MYH11 copy number ratios 410 during CR had a significantly shorter relapse-free survival (P ¼ 0.002) and higher risk of relapse (P ¼ 0.05) than patients with copy numbers o10.
Taken together, the available data generally support the feasibility and utility of sensitive detection and quantification of CBFb/MYH11 transcripts by real-time RT-PCR in the follow-up of patients with inv(16)-positive AML. The data from Guerrasio et al 1 confirm our earlier conclusion 2 that it is possible to determine in remission samples a CBFb/MYH11 transcript copy number threshold above which relapse occurs and below which continuous CR is likely. Further studies should pinpoint the threshold value more precisely. 
